Response by Zhou Et Al to Letter Regarding Article, "cardioprotective Role of Myeloid-Derived Suppressor Cells in Heart Failure".
Ling Zhou,Zhuoya Li,Dao Wen Wang
DOI: https://doi.org/10.1161/circulationaha.118.038022
IF: 37.8
2019-01-01
Circulation
Abstract:January 8, 2019 301 Ling Zhou, MD, PhD Zhuoya Li, MD, PhD Dao Wen Wang, MD, PhD In Response: We thank Dr Moris and colleagues for their interest in our recently published article, which revealed a cardioprotective role of myeloid-derived suppressor cells (MDSCs) in heart failure (HF) by their antihypertrophic effects and anti-inflammatory effects through interleukin-10 and nitric oxide.1 Programmed cell death protein 1 (PD-1) is a cell surface receptor that is expressed on T cells and pro-B cells and, ligating with its ligands PD-L1 and PD-L2, suppresses T-cell responses to self and microbial antigens. It is well known that MDSCs express PD-L1, which is associated with their suppressive effects, including interleukin-10 production. Our study demonstrated that the increased serum level of interleukin-10 in patients with HF was positively correlated with MDSC proportion, and neutralization of interleukin-10 blunted MDSC-mediated antiinflammatory and antihypertrophic effects.1 Therefore, the anti-inflammatory and antihypertrophic effects of MDSCs may be related to the PD-1/PD-L1 signaling pathway. It has been reported that PD-1 plays an important role in protecting the heart against T cell–mediated injury. Lu et al2 found that interferon-γ derived from alloreactive effector T cells upregulates PD-L1 expression in mesenchymal cells, which in turn facilitates the death of effector T cells. Similarly, neutralization of interferon-γ has been found to significantly decrease PD-L1+ MDSCs, and targeting PD-L1 partially impairs MDSC-mediated T-cell suppression.3 A wealth of studies indicates that regulatory T (Treg) cells have a cardioprotective role in cardiovascular diseases, including hypertension, myocardial infarction and remodeling, myocarditis, dilated cardiomyopathy, and HF. Although activation and expansion of Treg cells are two of the suppressive activities of MDSCs, in contrast to increased frequency of MDSCs in patients with HF, the number of Treg cells is significantly decreased. Li et al4 reported that the Th17/Treg imbalance exists in patients with chronic HF and that under inflammatory conditions, in the presence of interleukin-2, Tregs can be converted into proinflammatory Th17 cells.5 This may be a reason for decreased Tregs in the setting of HF. However, the relationship between MDSCs and Th17 in HF remains obscure, although there are a large number of contradictory reports on the interplay between these 2 types of cells in tumor and autoimmune diseases.